Concord Medical Services Holdings Limited (CCM)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Concord Medical Services Holdings Limited (CCM) trades at $4.60 with AI Score 24/100 (Grade F). Concord Medical Services Holdings Limited operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. Market cap: $669,824, Sector: Healthcare.
Price live · AI analysis from Mar 15, 2026Analyst Coverage for CCM: CCM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CCM against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CCM: 1/1 perspectives are bearish.
How is this calculated? →Concord Medical Services Holdings Limited (CCM) Healthcare & Pipeline Overview
Concord Medical Services Holdings Limited, based in China, operates a network of radiotherapy and diagnostic imaging centers. The company offers a comprehensive suite of cancer treatment and diagnostic services, including radiotherapy, gamma knife radiosurgery, and diagnostic imaging. It also provides clinical support and equipment leasing, positioning it as an integrated oncology solutions provider.
What Is the Investment Thesis for CCM?
Concord Medical Services Holdings Limited presents a complex investment case. The company's negative profit and gross margins (-44.6% and -11.4% respectively) indicate significant challenges in achieving profitability. The company's beta of -1.23 suggests an inverse correlation to the market, which may appeal to investors seeking diversification. Growth catalysts include expanding its network of cooperative centers and hospitals, and increasing adoption of advanced radiotherapy techniques. However, investors should closely monitor the company's ability to improve its financial performance and navigate the regulatory landscape in China's healthcare sector.
Based on FMP financials and quantitative analysis
CCM Key Highlights
- Operates a network of 16 cooperative centers based in 13 hospitals as of December 31, 2021.
- Offers a range of radiotherapy services, including linear accelerator external beam radiotherapy and gamma knife radiosurgery.
- Provides diagnostic imaging services, including computed tomography (CT) scans.
- Offers clinical support services, such as developing treatment protocols and organizing joint diagnoses.
- Operates specialty cancer hospitals providing radiotherapy, diagnostic imaging, chemotherapy, and surgery.
Who Are CCM's Competitors?
CCM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CELU Celularity Inc. | $0.79 | +27.48% | $19.00M | — |
| HWAIF Healwell AI Inc. | $0.53 | -3.52% | $160.75M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
| SLHGP Skylight Health Group Inc. | $12.00 | -5.88% | 61 | |
| NWKHY Netcare Limited | $7.17 | +0.00% | $843.64M | 50 |
| AONC American Oncology Network, Inc. | $10.00 | +0.00% | $292.48M | 50 |
| DCGO DocGo Inc. | $0.59 | +5.81% | $58.07M | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CCM's Key Strengths?
- Established network of radiotherapy and diagnostic imaging centers in China.
- Comprehensive suite of cancer treatment services.
- Expertise in advanced radiotherapy techniques.
- Strong relationships with hospitals and medical professionals.
What Are CCM's Weaknesses?
- Negative profit margin and gross margin.
- Reliance on cooperative centers within hospitals.
- Exposure to regulatory risks in China's healthcare sector.
- Limited geographic diversification.
What Could Drive CCM Stock Higher?
- Expansion of the network of cooperative centers and specialty cancer hospitals.
- Increasing adoption of advanced radiotherapy techniques, such as IMRT and SBRT.
- Strategic partnerships with other healthcare providers and technology companies.
What Are the Key Risks for CCM?
- Financial-distress signal — its Altman Z-Score of -1.26 sits in the distress zone (elevated bankruptcy risk).
- Negative profit margin and gross margin, indicating financial challenges.
- Changes in government regulations and healthcare policies in China.
- Competition from other radiotherapy and diagnostic imaging providers.
- Technological advancements that could render existing equipment obsolete.
What Are the Growth Opportunities for CCM?
- Expansion of Cooperative Centers: Concord Medical has the opportunity to expand its network of cooperative centers within existing and new hospitals across China. This expansion can increase its geographic reach and patient access, driving revenue growth. The market for radiotherapy services in China is projected to grow, driven by increasing cancer incidence and government support for advanced medical technologies. A realistic timeline for adding 2-3 centers per year over the next 3-5 years could significantly boost revenue.
- Adoption of Advanced Radiotherapy Techniques: The company can drive growth by promoting the adoption of advanced radiotherapy techniques, such as intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT). These techniques offer more precise and effective cancer treatment, attracting patients seeking advanced care. The market for advanced radiotherapy is growing rapidly, with increasing demand from both patients and physicians. Concord Medical can invest in training and technology to become a leader in this area.
- Development of Specialty Cancer Hospitals: Concord Medical can further develop its specialty cancer hospitals, offering a full range of cancer treatments, including radiotherapy, diagnostic imaging, chemotherapy, and surgery. This integrated approach can attract patients seeking comprehensive cancer care under one roof. The market for specialty cancer hospitals is growing, driven by increasing demand for specialized cancer treatment services. The company can invest in expanding its hospital network and enhancing its service offerings.
- Strategic Partnerships: Concord Medical can pursue strategic partnerships with other healthcare providers, research institutions, and technology companies to expand its service offerings and market reach. These partnerships can provide access to new technologies, expertise, and patient networks. The healthcare industry is increasingly collaborative, with companies forming partnerships to leverage each other's strengths. Concord Medical can explore partnerships with companies specializing in areas such as genomics, immunotherapy, and artificial intelligence.
- Teleconsultation and Medical IT Services: The company can leverage teleconsultation and medical IT services to improve patient access and streamline operations. Teleconsultation can enable remote consultations with specialists, while medical IT services can improve data management and treatment planning. The market for telemedicine and medical IT is growing rapidly, driven by increasing adoption of digital health technologies. Concord Medical can invest in developing its teleconsultation platform and medical IT infrastructure.
What Opportunities Does CCM Have?
- Expansion of cooperative centers and specialty cancer hospitals.
- Adoption of advanced radiotherapy techniques.
- Strategic partnerships with other healthcare providers.
- Growth in China's healthcare market.
What Threats Does CCM Face?
- Competition from other radiotherapy and diagnostic imaging providers.
- Changes in government regulations and healthcare policies.
- Technological advancements that could render existing equipment obsolete.
- Economic downturn in China.
What Are CCM's Competitive Advantages?
- Established network of cooperative centers and hospitals across China.
- Comprehensive suite of cancer treatment and diagnostic services.
- Expertise in radiotherapy and diagnostic imaging.
- Strong relationships with hospitals and medical professionals.
What Does CCM Do?
Founded in 1997 and headquartered in Beijing, Concord Medical Services Holdings Limited operates a network of radiotherapy and diagnostic imaging centers across the People's Republic of China. The company has evolved into a comprehensive provider of cancer treatment solutions, operating through two primary segments: Network and Hospital. The Network segment focuses on providing radiotherapy and diagnostic imaging services through cooperative centers located within hospitals. These services include linear accelerator-based external beam radiotherapy, gamma knife radiosurgery, and diagnostic imaging using computed tomography scanners. Concord Medical also offers clinical support services, such as developing treatment protocols, organizing joint diagnoses, and assisting with the recruitment and compensation of medical personnel. The Hospital segment involves the operation of specialty cancer hospitals, offering a full spectrum of cancer treatments, including radiotherapy, diagnostic imaging, chemotherapy, and surgery. As of December 31, 2021, Concord Medical operated 16 cooperative centers in 13 hospitals. In addition to its core services, the company engages in radiotherapy and diagnostic equipment leasing, management services, premium cancer and proton treatment services, teleconsultation, and medical information technology services. It also sells medical equipment.
What Products and Services Does CCM Offer?
- Operates a network of radiotherapy and diagnostic imaging centers in China.
- Provides linear accelerator external beam radiotherapy.
- Offers gamma knife radiosurgery for head and body tumors.
- Performs diagnostic imaging services using CT scanners.
- Provides clinical support services to doctors.
- Offers radiotherapy and diagnostic equipment leasing.
- Operates specialty cancer hospitals offering comprehensive cancer treatments.
How Does CCM Make Money?
- Generates revenue from radiotherapy and diagnostic imaging services provided through its network of cooperative centers.
- Earns revenue from the operation of specialty cancer hospitals, offering a range of cancer treatments.
- Derives income from leasing radiotherapy and diagnostic equipment to hospitals.
- Receives fees for providing management services to hospitals.
- Generates revenue from the sale of medical equipment.
What Industry Does CCM Operate In?
Concord Medical Services Holdings Limited operates within China's growing healthcare market, specifically in the oncology sector. The demand for cancer treatment services is increasing due to an aging population and rising cancer rates. The competitive landscape includes both domestic and international players offering similar radiotherapy and diagnostic imaging services. Concord Medical differentiates itself through its network of cooperative centers and hospitals, providing a comprehensive suite of cancer treatment solutions. The industry is subject to regulatory oversight and technological advancements, requiring companies to adapt to changing market dynamics.
Who Are CCM's Key Customers?
- Patients seeking radiotherapy and diagnostic imaging services.
- Hospitals that partner with Concord Medical to establish cooperative centers.
- Hospitals that lease radiotherapy and diagnostic equipment from Concord Medical.
- Patients seeking comprehensive cancer treatment at Concord Medical's specialty cancer hospitals.
ROE 7%Key Financial Metrics
Return on equity for Concord Medical Services Holdings Limited stands at 7.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -2.4%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.48 means current liabilities exceed short-term assets, a liquidity point worth watching.
Concord Medical Services Holdings Limited (CCM) Valuation Context
Valued at 670K, CCM is classified as a micro-cap stock. Relative to its peer group, CCM's quantitative score of 24/100 is below the peer average of 63/100.
Company Profile
Concord Medical Services Holdings Limited operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Beijing, CN. The company is led by CEO Jianyu Yang. CCM has traded publicly since 2009.
F-Score 6/9Financial Health
Concord Medical Services Holdings Limited's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -1.26 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Concord Medical Services Holdings Limited revenue of about $440.4M for fiscal 2026, with EPS near $-18.25.
CCM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying hints that those in the know see long-term value, suggesting potential upside.
- The community seems to be buzzing about potential new partnerships, which could expand their market reach.
- Positive chatter suggests a growing belief in their innovative approach to medical services.
- Market perception seems to be shifting towards recognizing their strategic importance in the evolving healthcare landscape.
Bear Case
- Recent insider selling, even if for personal reasons, can create short-term selling pressure and erode confidence.
- Community sentiment reveals concerns about increasing competition in their sector, potentially impacting market share.
- Bearish views highlight worries about regulatory hurdles affecting future growth prospects.
- Market perception is clouded by uncertainty regarding their long-term financial stability, creating investor hesitation.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CCM Latest News
-
Asian Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
MT Newswires · Jun 15, 2026
-
ComplianceCow to Demonstrate Generative AI-Powered CCM 3.0 Controls in ServiceNow IRM
businesswire.com · Jun 11, 2026
-
RegScale Achieves ISO 27001 Certification in Under 30 Days Using Its Own Continuous Controls Monitoring Platform
businesswire.com · Jun 11, 2026
-
Wellgistics Health Announces Pilot MSO Collaboration with Kare PharmTech Targeting $14 Billion U.S. Market for CCM and RPM Services
accessnewswire.com · May 13, 2026
CCM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CCM.
Price Targets
Wall Street price target analysis for CCM.
CCM MoonshotScore
What does this score mean?
The MoonshotScore rates CCM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Asian Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
ComplianceCow to Demonstrate Generative AI-Powered CCM 3.0 Controls in ServiceNow IRM
RegScale Achieves ISO 27001 Certification in Under 30 Days Using Its Own Continuous Controls Monitoring Platform
Wellgistics Health Announces Pilot MSO Collaboration with Kare PharmTech Targeting $14 Billion U.S. Market for CCM and RPM Services
Leadership: Jianyu Yang
CEO
Jianyu Yang is the Chief Executive Officer of Concord Medical Services Holdings Limited. Information regarding his detailed career history and educational background is not available in the provided data. As CEO, he is responsible for the overall strategic direction and operational management of the company.
Track Record: Under Jianyu Yang's leadership, Concord Medical Services Holdings Limited has continued to operate a network of radiotherapy and diagnostic imaging centers in China. Specific milestones and achievements under his tenure are not detailed in the provided data.
Concord Medical Services Holdings Limited ADR Information
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company's stock, allowing it to trade on U.S. stock exchanges. For Concord Medical (CCM), each ADR represents a certain number of ordinary shares of the company traded on its home market. This allows US investors to invest in Concord Medical more easily.
- Home Market Ticker: Not specified in provided data. Primary stock exchange and country is required.
What Investors Ask About Concord Medical Services Holdings Limited (CCM) — Healthcare
What does Concord Medical Services Holdings Limited do?
Concord Medical Services Holdings Limited operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company provides a range of services, including linear accelerator external beam radiotherapy, gamma knife radiosurgery, and diagnostic imaging services using computed tomography scanners. It also operates specialty cancer hospitals, offering a full spectrum of cancer treatments, including radiotherapy, diagnostic imaging, chemotherapy, and surgery. Concord Medical also provides clinical support services, equipment leasing, and teleconsultation services.
What do analysts say about CCM stock?
There is no analyst consensus available in the provided data. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions. Key valuation metrics to consider include the company's market capitalization, price-to-earnings ratio, profit margin, and gross margin. Growth considerations include the company's ability to expand its network of cooperative centers and hospitals, and to increase adoption of advanced radiotherapy techniques.
What are the main risks for CCM?
The main risks for Concord Medical Services Holdings Limited include its negative profit margin and gross margin, indicating financial challenges. The company is also exposed to regulatory risks in China's healthcare sector, as well as competition from other radiotherapy and diagnostic imaging providers. Technological advancements could also render existing equipment obsolete. Additionally, as an ADR, the company is exposed to currency risk related to fluctuations in the exchange rate between the U.S. dollar and the Chinese Yuan.
What are the key factors to evaluate for CCM?
Concord Medical Services Holdings Limited (CCM) holds an AI score of 24/100 (low). Not financial advice.
How frequently does CCM data refresh on this page?
CCM prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CCM's recent stock price performance?
Concord Medical Services Holdings Limited (CCM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established network of radiotherapy and diagnostic imaging centers in China. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CCM overvalued or undervalued right now?
Valuing Concord Medical Services Holdings Limited (CCM) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CCM?
Before investing in Concord Medical Services Holdings Limited (CCM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited to the provided information.
- Analyst consensus is not available.
- CEO background information is limited.